Completed PHASE2 INTERVENTIONAL NCT00230581

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea

Sponsor: Dynogen Pharmaceuticals

Conditions Irritable Bowel Syndrome

Interventions DDP225

Updated 6 times since 2017 Last updated: Oct 12, 2007 Started: Sep 30, 2005 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Irritable Bowel Syndrome, this trial is completed. The trial is conducted by Dynogen Pharmaceuticals and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dynogen Pharmaceuticals

Data source: Dynogen Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Great Neck, United States , Greer, United States , Halifax, Canada , Hamilton, Canada , Kingston, Canada , London, Canada , Mogadore, United States , Ottawa, Canada , Québec, Canada , Sarnia, Canada and 3 more locations